These hepatic changes were accompanied by a marked increase in plasma levels of angiopoietin-like 3 (ANGPTL3), a key biomarker associated with metabolic disorders and lipid dysregulation. This evidence concerns the gene ANGPTL3 and Other metabolic disease.